anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Peripheral neuropathy is a debilitating disease of the nerves which can be a dose-limiting toxicity of chemotherapeutic agents. The symptoms of peripheral neuropathy can lead to considerable patient distress and discomfort, discontinuation of chemotherapy, and limitations regarding the selection of future chemotherapeutic regimens. Symptoms such as numbness, weakness, burning pain (especially at night), and loss of reflexes may take months before they improve and permanent deficits may remain. Epoetin alfa, already used in the treatment of chemotherapy-induced anemia, has been shown to have neuroprotective effects in preclinical studies. The purpose of this randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), placebo-controlled study is to evaluate the neuroprotective effect of PROCRIT (epoetin alfa) administered once every week in patients with cancer who develop chemotherapy-induced peripheral neuropathy due to treatment with combination Taxane and Platinum-Based chemotherapy. Patients will receive injections subcutaneously or intravenously of either epoetin alfa or placebo once weekly for up to 18 weeks. Doses may be adjusted in the range of 20,000 to 60,000 Units once a week, depending on the patient's hemoglobin levels. Safety evaluations will be conducted throughout the study at specified intervals and will consist of assessment of laboratory tests (Hemoglobin level, Complete Blood Count (CBC), Blood Chemistries), vital signs, physical examinations and occurrence and severity of adverse events. In addition, the occurrence of anti-erythropoietin antibodies at baseline and study completion/early withdrawal will be evaluated in patients who received PROCRIT (Epoetin alfa) after database lock and unblinding has occurred. The primary measure of effectiveness is the change at Week 12 in the National Cancer Institute Common Toxicity Criteria (NCI CTC) neuropathy score. The study hypothesis is that epoetin alfa will be more effective in the treatment of chemotherapy-induced peripheral neuropathy than placebo as measured at Week 12 by the National Cancer Institute Common Toxicity Criteria (NCI CTC) neuropathy score. Patients will receive injections subcutaneously (SC, under the skin) or intravenously (IV, in a vein) of either epoetin alfa or placebo once weekly for up to 18 weeks. Doses may be adjusted depending on the patient's hemoglobin levels to the maximum 60,000 Units once a week. The minimum dose can be 20,000 Units once a week.
NEW MATERIAL:A L-xylopyranosideplatinum complex of formula I (R is H, alkyl, alkenyl, etc,: X is halogen, -SCN, -NO3, etc.). EXAMPLE:Dichloro-(benzyl 3,4-diamino-3,4-dideoxy-L-xylopyranoside)platinum. USE:Antineoplastic agents. High in antineoplastic activity and low toxic. PREPARATION:For example, an aqueous solution of a halogenated primary platinate of formula M2Pt(Hal)4 (M is H or atom convertible to monovalent cation; Hal is halogen) (pref. potassium halogenated primary platinate) is added to an ethanol solution of amino sugar of formula II followed by reaction at 40-70 deg.C for 1-24hr to obtain a compound of the formula I (X is halogen). The amount of the halogenated primary platinate to be used is such as to be 1-2 molar times that for the amino sugar.
Long-term carcinogenicity studies were conducted with rifabutin in mice and in rats. Rifabutin was not carcinogenic in mice at doses up to 180 mg/kg/day, or approximately 36 times the recommended human daily dose. Rifabutin was not carcinogenic in the rat at doses up to 60 mg/kg/day, about 12 times the recommended human dose.

Rifabutin was not mutagenic in the bacterial mutation assay (Ames Test) using both rifabutin-susceptible and resistant strains. Rifabutin was not mutagenic in Schizosaccharomyces pombe P1 and was not genotoxic in V-79 Chinese hamster cells, human lymphocytes in vitro, or mouse bone marrow cells in vivo.

Fertility was impaired in male rats given 160 mg/kg (32 times the recommended human daily dose).
The present invention relates to a magnetic nano crystal which is prepared with the ''one-port'' method and can be highly dissolved and steadily dispersed in the biological buffer liquid. Under the condition that the biocompatibility polymer exits or the biocompatibility polymer, the small-molecule amine with alkyl chain, carboxyl acid or alcohol exist together, the metal precursor is decomposed with high temperature in the high boiling point nonpolar or high boiling point weak-polar solvent for preparing the high-crystallinity magnetic nano crystal with different kind, different dimension and different shapes. The technical method adopted by the invention has the characters of simple technique, easy operation. The grain diameter of the magnetic nano crystal prepared with the technique has the advantages of uniformity, controllability, high crystallinity, strong magnetic response and good biocompatibility. Most important, the dry powder of the obtained magnetic nano crystal still represents excellent dissolvability after placing in the biological buffer liquid for a long time. Therefore, the biocompatibility magnetic nano crystal prepared by the technical method has the characters of easy storing and transportation, and is suitable for large-scale and commercial production.
This is a non-randomized open-label study in approximately 10-15 adolescent and adult participants between ages 12 to \<75 years with severe hemophilia A (defined as FVIII activity \<1%) with or without inhibitors who are currently on treatment with emicizumab for ≥6 months. The study is designed to assess the safety and PK/PD during a 4-month treatment period with marstacimab 150 mg SC QW after a 14-day wash-out period following discontinuation of emicizumab. The anticipated study duration for an individual participant is approximately 6 months. Assessment of safety will be conducted by summarizing AEs and SAEs reported during the study, from before the wash-out of emicizumab until after participants have resumed prophylactic therapy per their standard of care. Participants will continue to use their standard of care factor replacement for breakthrough bleeds during the course of the study. PK, PD, and ADA measurements will support the clinical safety data.
Following on from the COVID-19 pandemic is another worldwide public health challenge that is referred to variously as long COVID, post-COVID syndrome or post-acute sequelae of SARS-CoV-2 infection (PASC). PASC comes in many forms and affects all body organs. This heterogeneous presentation suggests involvement of the autonomic nervous system (ANS), which has numerous roles in the maintenance of homeostasis and coordination of responses to various stressors. Thus far, studies of ANS dysregulation in people with PASC have been largely observational and descriptive, based on symptom inventories or objective but indirect measures of cardiovascular function, and have paid little attention to the adrenomedullary, hormonal and enteric nervous components of the ANS. Such investigations do not consider the syndromic nature of autonomic dysfunction. This Review provides an update on the literature relating to ANS abnormalities in people with post-COVID syndrome and presents a theoretical perspective on how the ANS might participate in common features of PASC.
Bone metastases are common in patients with advanced lung cancer and can have devastating consequences. which can lead to pain, decreased mobility and skeletal complications .Preventing or delaying bone metastases may improve outcomes. Bisphosphonates are inhibitors of osteoclast-mediated bone resorption. The current indications for bisphosphonates include the treatment of metabolic disorders of bone metabolism (e.g., osteoporosis and Paget's disease), the treatment of hypercalcaemia of malignancy (HCM), and the prevention of SREs from malignant bone disease. Clinical trials also confirm that bisphosphonates, and zoledronic acid in particular, can prevent bone loss from cancer treatment.There is also emerging evidence that the benefits of bisphosphonate therapy in the oncology setting are more extensive. This study will evaluate whether the addition of ZOL 4 mg every 3 months for up to 1 years in patients with stage IIIB/IV lung cancer could reduce the rate of bone metastases ,improve progression-free survival (PFS) and overall survival(OS), and delay time to bone metastases .
We determined the in vivo counteracting effect of fiber and probiotic supplementation on colonic mucosal damage and alterations in gut microbiota caused by 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) and sodium dextran sulfate (DSS). Male Fischer-344 rats were randomly divided into 4 groups: control (standard diet), PhIP + DSS group (standard diet + PhIP + DSS), fiber (fiber diet + PhIP + DSS), and probiotic (probiotic diet + PhIP + DSS). The intake of PhIP + DSS for 3 weeks induced colonic mucosal erosion, crypt loss, and inflammation, and the distal colon was more severely damaged. Fiber alleviated colonic mucosal damage by reducing crypt loss and inflammation, while the probiotic increased colon length. The intake of PhIP + DSS increased the fecal relative abundance of Clostridia UCG014 along the intervention, in contrast to the lower abundances of these taxa found after PhIP + DSS administration in the rats supplemented with probiotics or fiber. Fiber supplementation mitigated the histological damage caused by PhIP + DSS shifting the gut microbiota toward a reduction of pro-inflammatory taxa.
Participants receive donepezil in doses up to 10 mg once daily (QD), orally in a scheduled titration for Days 1-56. The total treatment duration is 56 days.
Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
PURPOSE:To obtain a leucocyte removing material and filter excellent in a leucocyte removing rate and having a low removing rate of blood platelet and an excellent hydropholic property by filling a vessel having the leucocyte removing material consisting of plasma treated unwoven fabric and an in-out port of leucocyte floating fluid, with the plasma treated unwoven fabric. CONSTITUTION:An unwoven fabric on the market can be used with no particular limitation, but an article of polypropylene, polyester, polyamide is preferable with a large effect. The unwoven fabric is used applying a plasma treatment. The plasma treatment is preferable being performed in unpolymerizable gas. By the plasma treatment thus obtained, because a blood platelet is suppressed from its adherence further with a hydrophilic property being given, a leucocyte removing material and filter obtained with easy priming operation by physiological salt water. In this way, the plasma treated unwoven fabric is used as the leucocyte removing filter with which a vessel, having an in-out port of leucocyte floating fluid, is filled.
Complementary and alternative therapies play an increasing role in the multidisciplinary treatment of primary pediatric headache disorders. Every pediatric headache patient needs to have a personalized and tailored program of education, psychological strategies, pharmacotherapy and complementary medicine choices. This particular study may prove desirable for parents of children and adolescents with chronic headache. As documented by Termine, C., Ferrari, Ginevra, O., D'Arrigo, S., Rossi, M., \& Lanzi, G. (2005), parents are often uncertain and fearful of submitting their children to treatment with traditional drugs, adolescents can use alternative therapies as a way of affirming their independence, and there are fewer drugs available to treat headache in children. Moreover, there is a 30-40% placebo response in headache sufferers (Mauskop, 2001). Children and adolescents should not be prevented from using alternative treatments, specifically essential oils, provided that the intervention is not harmful or costly. It is hoped this study will contribute to the scant research that exists and help define the indications, effects and limitations of aromatherapy use.
A 4-week experimental diet with all meals and foods be provided to participants, including 90g of regular cheddar cheese daily per 2500 kcal. The diet will contain 13% of saturated fat (SFA), 14% of mono-unsaturated fat (MUFA), 5% of polyunsaturated fat (PUFA) and 53% of carbohydrate (CHO).
PURPOSE: To prevent thromboarterio-atresia, and also reduce the necessity for anticoagulant treatment by performing an anti-thrombogenic coating on a stent. CONSTITUTION: Two rings of a spiral coil spring stent manufactured from single metal or alloy radiated to make a radioactive substance such as a radioisotope are embedded in a plaque in an arterial wall AW. Omnidirectional irradiation of a particle from a stent wire turning to the outside 12 from a cross section 10 reduces a growth rate of a hyperplastic cell of the artierial wall AW causing a trauma. A radioisotope used for this purpose is emissions of alpha, beta and gamma. As an optimal condition of the emissions a beta emission isotope such as vanadium 48 having a half-life of 16 days may be good, and an ideal attribute of a beta emission is radioactivity of not being transmitted so much to tissue of a human being. The other method to make a material of a stent spring wire is performed from metal among kinds to make an emission makable in a radioisotope into alloy.  Beta emitting isotope gold 198 (a half-life of 2.7 days) is used to cover an optional proper spring metallic material.
PURPOSE:To obtain a cosmetic effective in promoting the metabolism of skin, smoothing the skin and softening the hair by compounding extract or squeezed juice of Corchorus olitorius to the skin or hair cosmetic base. CONSTITUTION:Leaf or whole grass of raw Corchorus olitorius is dried, cut to small pieces and extracted with water or an organic solvent (e.g. 1,3-butylene glycol or ethanol) or their mixture at normal temperature or under heating and the extracted liquid is concentrated. The concentrated extract or a squeezed juice of raw Corchorus olitorius (containing vitamins, Ca, K, uronic acid, mucopolysaccharide, etc.) is compounded to a skin or hair cosmetic base to obtain the objective cosmetic exhibiting excellent effect for beauty and health. When the cosmetic is applied to the skin, it promotes the metabolism without injuring the skin, suppresses pimples, makes smooth skin and exhibits the remedying and preventing effect for the chapped skin and aging. It gives refreshing and glossy hair when applied to the hair.
Because of the potential of 5-HT1 agonists to cause coronary vasospasm, eletriptan should not be given to patients with documented ischemic or vasospastic coronary artery disease (CAD) (see CONTRAINDICATIONS). It is strongly recommended that eletriptan not be given to patients in whom unrecognized CAD is predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery vasospasm is modest, at best. If, during the cardiovascular evaluation, the patient's medical history, electrocardiographic, or other investigations reveal findings indicative of, or consistent with coronary artery vasospasm or myocardial ischemia, eletriptan should not be administered (see CONTRAINDICATIONS).

For patients with risk factors predictive of CAD, who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of eletriptan take place in the setting of a physician's office or similar medically staffed and equipped facility unless the patient has previously received eletriptan. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following administration of RELPAX Tablets, in these patients with risk factors.

It is recommended that patients who are intermittent long-term users of 5-HT1 agonists including RELPAX Tablets, and who have or acquire risk factors predictive of CAD, as described above, undergo periodic cardiovascular evaluation as they continue to use RELPAX Tablets.

The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to eletriptan.
Improvement in asthma control following inhalation can occur within 24 hours of beginning treatment in some patients, although maximum benefit may not be achieved for 1 to 2 weeks, or longer. The effects of QVAR on the hypothalamic-pituitary-adrenal (HPA) axis were studied in 40 corticosteroid naive patients. QVAR, at doses of 80, 160 or 320 mcg twice daily was compared with placebo and 336 mcg twice daily of beclomethasone dipropionate in a CFC propellant based formulation (CFC-BDP). Active treatment groups showed an expected dose-related reduction in 24-hour urinary free cortisol (a sensitive marker of adrenal production of cortisol). Patients treated with the highest recommended dose of QVAR (320 mcg twice daily) had a 37.3% reduction in 24-hour urinary free cortisol compared to a reduction of 47.3% produced by treatment with 336 mcg twice daily of CFC-BDP. There was a 12.2% reduction in 24 hour urinary free cortisol seen in the group of patients that received 80 mcg twice daily of QVAR and a 24.6% reduction in the group of patients that received 160 mcg twice daily. An open label study of 354 asthma patients given QVAR at recommended doses for one year assessed the effect of QVAR treatment on the HPA axis (as measured by both morning and stimulated plasma cortisol). Less than 1% of patients treated for one year with QVAR had an abnormal response (peak less than 18 mcg/dL) to short-cosyntropin test.
Erythema, scaling, dryness, and stinging/burning may be experienced with use of adapalene and benzoyl peroxide gel 0.1% / 2.5%. These are most likely to occur during the first four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the medication. Irritant and allergic contact dermatitis may occur. Depending upon the severity of these adverse reactions, patients should be instructed to use a moisturizer, reduce the frequency of the application of adapalene and benzoyl peroxide gel 0.1% / 2.5%, or discontinue use. The product should not be applied to cuts, abrasions, eczematous or sunburned skin. As with other retinoids, use of “waxing” as a depilatory method should be avoided on skin treated with adapalene and benzoyl peroxide gel 0.1% / 2.5%.  
  
Avoid concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have strong skin-drying effect and products with high concentrations of alcohol, astringents, spices, or limes).
The synapses between inner hair cells (IHCs) and spiral ganglion neurons (SGNs) are the most vulnerable structures in the noise-exposed cochlea. Cochlear synaptopathy results from the disruption of these synapses following noise exposure and is considered the main cause of poor speech understanding in noisy environments, even when audiogram results are normal. Cochlear synaptopathy leads to the degeneration of SGNs if damaged IHC-SGN synapses are not promptly recovered. Oxidative stress plays a central role in the pathogenesis of cochlear synaptopathy. C-Phycocyanin (C-PC) has antioxidant and anti-inflammatory activities and is widely utilized in the food and drug industry. However, the effect of the C-PC on noise-induced cochlear damage is unknown. We first investigated the therapeutic effect of C-PC on noise-induced cochlear synaptopathy. In vitro experiments revealed that C-PC reduced the H2O2-induced generation of reactive oxygen species in HEI-OC1 auditory cells. H2O2-induced cytotoxicity in HEI-OC1 cells was reduced with C-PC treatment. After white noise exposure for 3 h at a sound pressure of 118 dB, the guinea pigs intratympanically administered 5 μg/mL C-PC exhibited greater wave I amplitudes in the auditory brainstem response, more IHC synaptic ribbons and more IHC-SGN synapses according to microscopic analysis than the saline-treated guinea pigs. Furthermore, the group treated with C-PC had less intense 4-hydroxynonenal and intercellular adhesion molecule-1 staining in the cochlea compared with the saline group. Our results suggest that C-PC improves cochlear synaptopathy by inhibiting noise-induced oxidative stress and the inflammatory response in the cochlea.
The embodiment of the invention provides a method, a device, equipment and a storage medium for analyzing associated disease, and relates to the technical field of medical assistance. The related disease species analysis method comprises the following steps: and S1, acquiring disease information of a plurality of patients. Wherein the disease information comprises disease symptoms and disease types of the patients. S2, acquiring an association table of disease symptoms and disease types according to the disease information. And S3, calculating the cascade degree of disease species combinations comprising a preset number of disease species in a layered mining mode according to the association table. And S4, acquiring the related disease combination according to the concatenation degree. And S5, generating diagnosis auxiliary information according to the relevant disease species combination. The related disease combination can be well identified from the medical data in a layered mining mode. Thereby assisting the doctor in diagnosis. Early prevention or finding of complications has good practical significance.